跳至主要内容
临床试验/NCT02733991
NCT02733991已完成不适用

Study of MiniMed™ 640G Insulin Pump With SmartGuard™ in Prevention of Low Glucose Events in Adults With Type 1 Diabetes

Medtronic Diabetes16 个研究点 分布在 4 个国家目标入组 153 人开始时间: 2016年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
153
试验地点
16
主要终点
Mean Number of Sensor Glucose Hypoglycaemic Events Below or Equal to 55 mg/dL Per Patient/Week.

研究概览

简要总结

A premarket, international multicenter, prospective, open label, adaptive, randomized controlled study.

The aim is to evaluate the efficacy of sensor augmented pump therapy with MiniMed™640G and SmartGuard™in preventing hypoglycemic events in comparison with continuous subcutaneous insulin infusion therapy in type 1 diabetes adults with an increased risk of hypoglycemia. The primary objective is to demonstrate a reduction in the mean number of hypoglycemic events when using the MiniMed™640G system with SmartGuard™ and the secondary objectives will aim at evaluating the difference in glycemic parameters and HbA1c.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
24 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 24-75 years old at time of screening.
  • Diagnosed with Type 1 diabetes ≥10 years prior to screening.
  • On pump therapy for ≥ 6 months prior to screening.
  • Not on Real Time continuous glucose monitoring for ≥ 3 months prior to screening.
  • HbA1c value ≥5.8% and ≤10.0% as assessed by local lab ≤ 15 days prior to screening or performed at screening.
  • A documented Severe Hypoglycemia event ≤ 12 months prior to screening, OR Clarke score ≥4 assessed at time of screening, OR
  • Gold score ≥4 assessed at time of screening.
  • Subject is willing to sign and date informed consent, comply with all study procedures and wear all study devices as required during the study.

排除标准

  • Untreated Addison's disease, thyroid disorder, growth hormone deficiency, hypopituitarism or definite gastroparesis, per investigator judgment.
  • Subject is using Pramlintide (Symlin) SGLT2 inhibitor, GLP agonist at time of screening.
  • Renal failure defined by creatinine clearance <30 ml/min, as assessed by local lab test ≤ 3 months before screening or performed at screening at local lab.
  • Hearing or vision impairment hindering perception of glucose display and alarms, or otherwise incapable of using the study devices, per investigator judgment.
  • Current pregnancy or intention to conceive.
  • Any unresolved adverse skin condition in the area of sensor placement (e.g. psoriasis, rash, Staphylococcus infection).
  • Alcohol or drug abuse, other than nicotine, per investigator judgment.
  • Any other disease or condition that may preclude the patient from participating in the study, per investigator judgment.
  • Legally incompetent, illiterate or vulnerable person.
  • Randomization Criteria:
  • If subjects meet the above criteria, as well as all of the following criteria assessed at the end of the run-in period, they may continue to participate in the treatment period of the study:
  • Subject has worn two weeks the sensor with transmitter during the run-in period.
  • Subject has shown acceptable tolerance of sensor wear, per investigator judgment.
  • Subject performed ≥ 4 finger stick blood glucose measurements daily, as determined by CareLink™ Clinical data upload as the mean number of SMBG/day over the past 14 days (SMBG number / day ≥ 3.5 rounds up to 4).
  • Subject showed ability to comprehend the pump training and study procedures, per investigator judgment.

结局指标

主要结局

Mean Number of Sensor Glucose Hypoglycaemic Events Below or Equal to 55 mg/dL Per Patient/Week.

时间窗: 6 months

次要结局

  • Mean Time Spent of Sensor Glucose Values Within Range and Including 70-180 mg/dL.(6 months)
  • Mean Time Spent of Sensor Glucose Values Below or Equal 55 mg/dL.(6 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (16)

Loading locations...

相似试验